| Tue, Feb 2, 2010 |
| • |
SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Tue, Feb 2)
|
| Fri, Jan 15, 2010 |
| • |
SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Fri, Jan 15)
|
| Wed, Jan 6, 2010 |
| • |
Neutral on Santarus
Zacks.com (Wed, Jan 6)
|
| Wed, Dec 30, 2009 |
| • |
Santarus Receives $20 Million
Zacks.com (Wed, Dec 30)
|
| • |
Santarus eyes Phase III trials for diarrhea drug
at MarketWatch (Wed, Dec 30)
|
| • |
Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Travelers Diarrhea
Business Wire (Wed, Dec 30)
|
| Wed, Dec 23, 2009 |
| • |
3 Stocks Ready to Roar
at Motley Fool (Wed, Dec 23)
|
| Tue, Dec 22, 2009 |
| • |
Santarus Receives Previously Announced $20 Million Milestone for FDA Approval of ZEGERID OTC
Business Wire (Tue, Dec 22)
|
| Tue, Dec 15, 2009 |
| • |
Santarus Lippert/Heilshorn Life Sciences Call scheduled for 10:30 am ET today
Vcall (Tue, Dec 15)
|
| Mon, Dec 14, 2009 |
| • |
Santarus Announces Webcast Presentation at the Lippert/Heilshorn Life Sciences Virtual Conference
Business Wire (Mon, Dec 14)
|
| Mon, Dec 7, 2009 |
| • |
Santarus, JA Solar: Early Volume Plays
at TheStreet.com (Mon, Dec 7)
|
| • |
SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Mon, Dec 7)
|
| Fri, Dec 4, 2009 |
| • |
Santarus Receives FDA Approval for Immediate-Release Omeprazole Tablet with Dual Buffers
Business Wire (Fri, Dec 4)
|
| Thu, Dec 3, 2009 |
| • |
I Love This Industry
at Motley Fool (Thu, Dec 3)
|
| • |
Santarus Announces Completion of Enrollment in European Phase III Clinical Trial for Budesonide MMX
Business Wire (Thu, Dec 3)
|
| Wed, Dec 2, 2009 |
| • |
Delta, Walgreen, Diedrich Coffee are big movers
AP (Wed, Dec 2)
|
| • |
Vertex Raising Money -- Again!: BioBuzz
at TheStreet.com (Wed, Dec 2)
|
| • |
Stock Picks: SNTS Up; WAG Down
at SmartMoney.com (Wed, Dec 2)
|
| • |
Premarket roundup: McDonald's, Santarus
AP (Wed, Dec 2)
|
| • |
Ahead of the Bell: Santarus soars on OTC Zegerid
AP (Wed, Dec 2)
|
| Older Headlines |
|
|
|
|
Help
0.01 (0.27%) 
Headlines
